Nicotine and ADHD: What the Patch Trials Found
Nicotine and ADHD: What the Patch Trials Found
Small, short placebo-controlled studies found that nicotine patches modestly reduced some ADHD symptoms in adults, with the largest reporting an 8% drop in a 52-person, two-day trial (Gehricke et al. 2009). That finding does not make nicotine a treatment. No nicotine product is approved for ADHD, nicotine is addictive (FDA), and the longest nicotine patch trial lasted just two days.
Key Takeaways
- Two placebo-controlled patch studies in adults with ADHD (n=17 and n=52) found short-term improvements in clinician-rated symptoms and self-reported ADHD symptoms, but both lasted days, not weeks or months.
- Adults with ADHD smoke at higher rates and quit at lower rates than the general population (Pomerleau et al. 1995).
- No nicotine product, including patches, gum, pouches or vapes, is FDA-approved to treat ADHD. Nicotine is a highly addictive chemical.
- In a 255-person trial, treating ADHD with methylphenidate did not improve quit rates over placebo in smokers who also wore nicotine patches (Winhusen et al. 2010).
Why people with ADHD reach for nicotine
Nicotine acts on the same neurotransmitter system that first-line ADHD medications target. The 1996 Conners trial abstract described nicotine as "an indirect dopamine agonist" that "improves attention and arousal," similar in mechanism to methylphenidate and dextroamphetamine (Conners et al. 1996). That overlap fuels the self-medication hypothesis: the idea, still a hypothesis, that people with ADHD may use nicotine because it seems to sharpen their focus for a while.
The numbers line up directionally. In a 1995 survey of 71 adults with ADHD, 42% of men and 38% of women were current smokers, versus 28.1% and 23.5% of the general population in 1991 (Pomerleau et al. 1995). A meta-analysis of longitudinal studies confirmed that children with ADHD were more likely to use nicotine and to develop nicotine dependence (Lee et al. 2011). With an estimated 15.5 million U.S. adults (6.0%) carrying a current ADHD diagnosis as of 2023 (CDC MMWR), the overlap is large.
What the nicotine trials in ADHD actually found
The controlled evidence is thin. Only two of the studies below gave actual nicotine (via patch) to adults with ADHD against a placebo. Three more tested two experimental nicotinic-receptor drugs. The sixth studied whether treating ADHD improves smoking cessation.
| Study | People | Design | Comparator | Result |
|---|---|---|---|---|
| Conners et al. 1996 | 17 adults with ADHD (6 smokers, 11 nonsmokers) | Acute double-blind crossover, nicotine patch 7 mg/day (nonsmokers) or 21 mg/day (smokers) | Placebo patch | Clinician-rated global improvement, better attention and timing measures; authors called for a longer trial |
| Gehricke et al. 2009 | 52 adults with ADHD (25 abstinent smokers, 27 nonsmokers) | Double-blind, 2 days nicotine patch vs 2 days placebo, everyday-life diaries | Placebo patch | ADHD symptom reports down 8%, negative mood down 9%; cardiovascular activity up for 3 to 6 hours after patch |
| Wilens et al. 1999 (ABT-418) | 32 adults with ADHD (29 completed) | Randomized double-blind crossover, two 3-week periods | Placebo | 40% improved vs 13%; symptom checklist down 28% vs 15%; dizziness and nausea most common side effects |
| Apostol et al. 2012 (ABT-089) | 221 enrolled, 171 analyzed | Randomized double-blind crossover, 4-week periods, 2 to 80 mg/day | Placebo | Beat placebo only at the two highest doses (40 mg once and twice daily) |
| Bain et al. 2012 (ABT-089) | 160 adults | Randomized double-blind parallel, 8 weeks, 40 or 80 mg/day | Placebo | No statistically significant effect on any efficacy measure |
| Winhusen et al. 2010 | 255 adult smokers with ADHD | Randomized double-blind, 11 weeks, all got 21 mg/day nicotine patch + counseling | OROS methylphenidate vs placebo pill | Quit rates 43.3% vs 42.2%, no difference; methylphenidate improved ADHD symptoms more |
Source: PubMed abstracts, checked Oct 2026.
Conners (1996) enrolled 17 people and ran for days. The authors found clinician-rated improvement and better performance on timed attention tasks, then concluded the "acute results indicate the need for a longer clinical trial" (PubMed).
Gehricke (2009) was larger (52 adults) and used real-world diaries. ADHD symptom reports fell 8% and negative mood fell 9% on nicotine days versus placebo days, regardless of smoking history, but cardiovascular activity also rose during the first 3 to 6 hours after the patch went on (PubMed).
ABT-418 and ABT-089 are experimental nicotinic-receptor drugs, not nicotine. ABT-418 showed promise in 32 adults over two three-week periods (Wilens et al. 1999). Abbott then developed ABT-089: one trial found it beat placebo only at the two highest doses, 40 mg once and twice daily (Apostol et al. 2012), and a second trial of 160 adults found no significant effect at any dose (Bain et al. 2012). Abbott funded both ABT-089 studies, and their authors worked for Abbott.
Does nicotine help ADHD?
In small, short placebo-controlled studies, nicotine patches modestly reduced some ADHD symptoms, but no study shows it is a safe or effective treatment, and nicotine is addictive.
The gap between "a two-day patch study showed an 8% symptom reduction" and "nicotine helps ADHD" is enormous. Neither actual nicotine patch trial lasted longer than two days. The two nicotine studies enrolled 17 and 52 people. The 52-person study raised cardiovascular activity alongside any symptom benefit. We found no published long-term trial of nicotine in ADHD. The pharmaceutical attempt to build on this signal with nicotinic-receptor drugs produced mixed-to-negative results across three trials totaling over 400 participants. The dopamine link is plausible. The evidence for a treatment is not there.
ADHD, nicotine dependence and quitting
Adults with ADHD also appear to have a harder time stopping. In the Pomerleau 1995 survey, only 29% of adults with ADHD who had ever smoked had successfully quit, compared with 48.5% in the general population (PubMed).
Does treating ADHD make quitting easier? Winhusen and colleagues tested this in 255 adult smokers with ADHD. All participants wore 21 mg/day nicotine patches and received weekly counseling; half also took OROS methylphenidate (up to 72 mg/day) and half a placebo pill. Methylphenidate improved ADHD symptom scores (P<.0001) and reduced cigarettes per day post-quit, but prolonged abstinence was nearly identical: 43.3% versus 42.2% (OR 1.1, P=.81). Blood pressure and heart rate rose to a statistically but not clinically significant degree (Winhusen et al. 2010).
A 2014 meta-analysis of 14 studies (n=2,360) found that stimulant treatment for ADHD was associated with lower smoking rates overall, but nearly all the included studies were naturalistic rather than randomized, so causal claims remain premature (Schoenfelder et al. 2014).
Pouches, vapes and patches deliver the same molecule
The delivery format changes speed and dose, but the compound is identical. A nicotine pouch, a vape and a transdermal patch all deliver nicotine, which the FDA describes as "a highly addictive chemical." FDA-approved nicotine replacement (patch, gum, lozenge) is approved to help adults quit smoking, not for ADHD.
A 2025 case report described a 21-year-old woman with ADHD who, after quitting smoking, used 10 to 12 nicotine pouches per day (6 mg each) who developed very high prolactin (312 ng/mL); levels normalized within days of stopping (Belcher et al. 2025). This is a single case, not general evidence, but it shows high-dose pouch use carries unknowns.
Before you change anything about ADHD treatment or nicotine
Talk to your prescriber before adjusting any ADHD medication, adding caffeine to a stimulant regimen, or starting or stopping nicotine. Stimulant medication and nicotine both raise heart rate and blood pressure; the Gehricke patch study found increased cardiovascular activity for hours after application, and in the Winhusen trial methylphenidate raised blood pressure and heart rate to a statistically, though not clinically, significant degree.
The federal minimum age to buy tobacco products is 21. If you or someone you know wants to quit smoking or nicotine, the free national quitline is 1-800-QUIT-NOW (1-800-784-8669).
Related from Roon
Frequently Asked Questions
Is nicotine a stimulant?
Yes, and the Conners abstract groups it with stimulant medicines as an indirect dopamine agonist; for the pharmacology, see Is Nicotine a Stimulant?
Is nicotine like Adderall?
Both act on the brain's dopamine system. The Conners 1996 abstract described nicotine as "an indirect dopamine agonist" alongside methylphenidate and dextroamphetamine (PubMed). But a shared neurotransmitter pathway does not make them equivalent. Adderall is a prescription ADHD medicine; nicotine is an addictive compound and is not approved to treat ADHD.
Do ZYNs help ADHD?
No study has tested nicotine pouches (ZYN or any other brand) for ADHD symptoms. The patch trials above used transdermal nicotine in controlled, short-term settings; they do not support pouch use for ADHD. ZYN contains nicotine, which is addictive. For the general attention data in adults without ADHD, see Do ZYNs Help You Focus?
Can you use nicotine patches for ADHD?
No. FDA-approved nicotine patches are approved to help adults quit smoking, not to treat ADHD. Using them off-label for attention is a question for your prescriber, not something to try based on two-day pilot studies.
Why is quitting nicotine harder with ADHD?
Pomerleau 1995 found a quit ratio of 29% among adults with ADHD versus 48.5% in the general population. In the Winhusen 2010 trial, treating ADHD with methylphenidate did not raise prolonged abstinence rates (43.3% vs 42.2%). If you want to quit, talk to your clinician, or call the free quitline at 1-800-QUIT-NOW.
A Caffeine Option With No Nicotine
Roon is not a treatment for ADHD; talk to your prescriber. If you take stimulant medication, ask them about caffeine too (more on that in Caffeine and ADHD).
What Roon is: a zero-nicotine caffeine pouch for adults who want caffeine without any nicotine. Inside one pouch: caffeine at 80 mg, L-theanine at 60 mg, methylliberine (Dynamine) at 25 mg and theacrine (TeaCrine) at 5 mg. Methylliberine slows caffeine clearance. A randomized, double-blind crossover PK study (n=12) found that co-administering methylliberine with caffeine extended caffeine's half-life from 7.2 to 15 hours with no increase in peak concentration (study). That study used 100 mg methylliberine and 150 mg caffeine, 4x and 1.9x Roon's doses, so the direction of the effect applies, not the exact magnitude. A longer half-life is not the same as hours of felt energy: people feel a pouch for roughly 6 to 8 hours, and your last pouch should land at least 8 hours before you plan to sleep.
If you are looking to drop nicotine pouches without giving up a focused oral habit, Roon is from $9.16 per tin on a 12-tin subscription. It does nothing for ADHD, and it contains no nicotine.
Sources
- Conners CK, Levin ED, et al. "Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)." Psychopharmacol Bull 1996;32(1):67-73. PubMed
- Gehricke JG, et al. "Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in adults with ADHD." Psychol Addict Behav 2009;23(4):644-55. PubMed
- Wilens TE, et al. "A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with ADHD." Am J Psychiatry 1999;156(12):1931-7. PubMed
- Apostol G, et al. "Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with ADHD." Psychopharmacology 2012;219(3):715-25. PubMed (Abbott-funded)
- Bain EE, et al. "A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-089 in adults with ADHD." J Clin Psychiatry 2012;73(6):783-9. PubMed (Abbott-funded)
- Winhusen TM, et al. "Impact of ADHD treatment on smoking cessation in ADHD smokers." J Clin Psychiatry 2010;71(12):1680-8. PubMed
- Pomerleau OF, et al. "Cigarette smoking in adult patients diagnosed with ADHD." J Subst Abuse 1995;7(3):373-8. PubMed
- Lee SS, et al. "Prospective association of childhood ADHD and substance use and abuse/dependence: A meta-analytic review." Clin Psychol Rev 2011;31(3):328-41. PubMed
- Schoenfelder EN, Faraone SV, Kollins SH. "Stimulant treatment of ADHD and cigarette smoking: A meta-analysis." Pediatrics 2014;133(6):1070-80. PubMed
- Belcher V, et al. "An unusual suspect: Hyperprolactinemia from nicotine pouches." AACE Endocrinol Diabetes 2025. PubMed
- CDC. "Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use Among U.S. Adults." MMWR 2024;73(40). CDC
- FDA. "Nicotine Is Why Tobacco Products Are Addictive." FDA
- FDA. "Want to Quit Smoking? FDA-Approved and FDA-Cleared Cessation Products Can Help." FDA
- FDA. "Tobacco 21." FDA
Written by Roon Team
